Latest News from: Wistar Institute

Filters close
Newswise: New Sugar-based Signature Identifies T Cells Where HIV Hides and Persists Despite Antiretroviral Therapy
Released: 7-Aug-2020 10:30 AM EDT
New Sugar-based Signature Identifies T Cells Where HIV Hides and Persists Despite Antiretroviral Therapy
Wistar Institute

Wistar scientists may have discovered a new way of identifying and targeting hidden HIV viral reservoirs during treatment with antiretroviral therapy (ART).

Newswise: New Molecular Mechanism Involved in Cellular Senescence That Modulates Inflammation and Response to Cancer Immunotherapy
Released: 19-Feb-2020 10:55 AM EST
New Molecular Mechanism Involved in Cellular Senescence That Modulates Inflammation and Response to Cancer Immunotherapy
Wistar Institute

Wistar scientists discovered a novel pathway that enables detection of DNA in the cytoplasm and triggers inflammation and cellular senescence. This pathway may be modulated during senescence-inducing chemotherapy to affect cancer cell response to checkpoint inhibitors.

Newswise: Wistar Joins Global Effort to Expedite Coronavirus Vaccine Development for Outbreak Originating in China
Released: 23-Jan-2020 1:50 PM EST
Wistar Joins Global Effort to Expedite Coronavirus Vaccine Development for Outbreak Originating in China
Wistar Institute

Wistar announces today that they are part of a team to develop a vaccine against the recently emerged strain of coronavirus (2019-nCoV) that has infected hundreds in China and other countries, including the U.S., and resulted in numerous deaths to date. Wistar is part of a collaboration funded by the Coalition for Epidemic Preparedness Innovations (CEPI).

Newswise: The Wistar Institute Received Nearly $2.5M in Philanthropic Support
Released: 19-Dec-2019 4:20 PM EST
The Wistar Institute Received Nearly $2.5M in Philanthropic Support
Wistar Institute

In the past six months, scientists at The Wistar Institute received funding from private foundations totaling $2,418,000 that will fuel new discoveries in cancer, immunology and infectious diseases.

Newswise: New Therapeutic Strategy for Chemotherapy Resistance in Ovarian Cancer
Released: 19-Dec-2019 10:40 AM EST
New Therapeutic Strategy for Chemotherapy Resistance in Ovarian Cancer
Wistar Institute

A Wistar study demonstrated that NAMPT, an enzyme critical for NAD+ biosynthesis, mediates selection of stem-like chemoresistant cells following cisplatin treatment.

Newswise: Microscopic World Comes Alive During Nikon Small World Exhibit
Released: 17-Dec-2019 3:55 PM EST
Microscopic World Comes Alive During Nikon Small World Exhibit
Wistar Institute

See cellular images as distinct as abstract art, minerals appear as future urban landscapes, single-celled organisms of the microscopic netherworld, and much more from the 2019 Nikon Small World competition of photomicrography.

Newswise: International Collaboration for Scientific Training Launched Between The Wistar Institute and Leiden University Medical Center in the Netherlands
Released: 15-Nov-2019 1:40 PM EST
International Collaboration for Scientific Training Launched Between The Wistar Institute and Leiden University Medical Center in the Netherlands
Wistar Institute

Wistar and Leiden University Medical Center (LUMC) formalized a memorandum of understanding between the two institutions to explore a postdoctoral training exchange program in immunology, cancer research and vaccine biology. The Wistar-Schoemaker International Postdoctoral Fellowship would bring recent Ph.D. graduates trained at LUMC to Wistar to advance their research education under the mentorship of cutting-edge biomedical research leaders.

Newswise:Video Embedded synthetic-dna-technology-applied-as-a-novel-strategy-for-delivery-of-anti-hiv-antibodies
VIDEO
Released: 8-Nov-2019 12:50 PM EST
Synthetic DNA Technology Applied as a Novel Strategy for Delivery of Anti-HIV Antibodies
Wistar Institute

Wistar scientists applied synthetic DNA-based technology to drive in vivo production of broadly neutralizing anti-HIV antibodies in small and large-animal models, providing proof of concept for a simple and effective next generation approach to HIV prevention and therapy. These results were published online in the Journal of Clinical Investigation.

Newswise: Wistar Institute Researcher Awarded American Cancer Society Research Professorship
Released: 22-Oct-2019 10:30 AM EDT
Wistar Institute Researcher Awarded American Cancer Society Research Professorship
Wistar Institute

The American Cancer Society has awarded a Research Professorship to Wistar's Dmitry l. Gabrilovich, M.D., Ph.D. This lifelong designation, accompanied by a five-year $400,000 commitment, is the most prestigious research grant made by ACS.

Newswise: $12.5 Million Grant Awarded to Wistar Extends Federal Support of the Institute’s Quest for Improved Targeted Therapies for Melanoma
Released: 17-Oct-2019 9:40 AM EDT
$12.5 Million Grant Awarded to Wistar Extends Federal Support of the Institute’s Quest for Improved Targeted Therapies for Melanoma
Wistar Institute

Wistar and collaborating institutions have received a major grant from the National Institutes of Health to further research on new melanoma targeted therapies integrating the role of the tumor microenvironment in influencing response to therapy and development of resistance.

Newswise: New Mechanism Fueling Brain Metastasis Discovered at Wistar
Released: 9-Oct-2019 11:05 AM EDT
New Mechanism Fueling Brain Metastasis Discovered at Wistar
Wistar Institute

Wistar scientists described a novel mechanism through which astrocytes, the most abundant supporting cells in the brain, also promote cancer cell growth and metastasis in the brain.

Newswise: Targeting a Novel Regulator of Mitochondrial Cell Death Delivers Anticancer Activity in Preclinical Studies
2-Oct-2019 3:05 PM EDT
Targeting a Novel Regulator of Mitochondrial Cell Death Delivers Anticancer Activity in Preclinical Studies
Wistar Institute

A novel anticancer molecule created by researchers at The Wistar Institute showed therapeutic activity in preclinical models of various cancer types.

Newswise: NIH New Innovator Award Given to Wistar Researcher to Unravel the Metabolic Link Between Diet, Alcohol Consumption and Cancer
1-Oct-2019 9:40 AM EDT
NIH New Innovator Award Given to Wistar Researcher to Unravel the Metabolic Link Between Diet, Alcohol Consumption and Cancer
Wistar Institute

The National Institutes of Health (NIH) today announced that Zachary T. Schug, Ph.D., assistant professor in the Molecular & Cellular Oncogenesis Program at Wistar, was awarded the prestigious NIH Director’s New Innovator Award in support of his research on the link between a high sugar/fat diet, alcohol use and cancer.

Newswise: Wistar Receives More than $12 Million to Fund 
Innovative Clinical Research on the Impact of Opioid Use on Response to Therapy in People Living with HIV
Released: 24-Sep-2019 10:05 AM EDT
Wistar Receives More than $12 Million to Fund Innovative Clinical Research on the Impact of Opioid Use on Response to Therapy in People Living with HIV
Wistar Institute

Wistar was awarded two major grants totaling more than $12 million from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to fund an international multidisciplinary clinical research consortium spearheaded by Wistar’s HIV Research Program.

Newswise: Identification of a Novel Regulator of Mitochondrial Cell Death Reveals a Promising Target for Cancer Therapy
Released: 19-Sep-2019 9:00 AM EDT
Identification of a Novel Regulator of Mitochondrial Cell Death Reveals a Promising Target for Cancer Therapy
Wistar Institute

Wistar researchers have described the role of mitochondrial fission factor (MFF) in controlling survival of cancer cells, suggesting the protein could represent a promising therapeutic target.

Newswise: Major Grant Awarded to Wistar Supports Development of a Novel Therapeutic Approach for Antibiotic-resistant Bacteria
Released: 12-Sep-2019 3:05 PM EDT
Major Grant Awarded to Wistar Supports Development of a Novel Therapeutic Approach for Antibiotic-resistant Bacteria
Wistar Institute

Wistar has received a grant of approximately $4.6 million from the National Institutes of Health in support of innovative research to tackle antibiotic resistance.

Newswise: Repeated Semen Exposure Promotes Host Resistance to Infection in Preclinical Model of HIV
20-Aug-2019 4:05 PM EDT
Repeated Semen Exposure Promotes Host Resistance to Infection in Preclinical Model of HIV
Wistar Institute

Contrary to the long-held view that semen can only act as a way to transmit HIV-1 from men to women, scientists at The Wistar Institute and the University of Puerto Rico found that frequent and sustained semen exposure can change the characteristics of the circulating and vaginal tissue immune cells that are targets for infection, reducing the susceptibility to a future infection.

Released: 22-May-2019 2:05 PM EDT
Novel Role in Spatial Chromosome Organization Identified for Frequently Mutated Cancer Protein
Wistar Institute

New research from The Wistar Institute sheds light on the function of the ARID1A protein, encoded by a gene that is among the most frequently mutated across human cancers.

Released: 15-May-2019 12:05 PM EDT
Enhanced Anticancer Compound May Allow for Precise Activation and Tracking of Treatment
Wistar Institute

Wistar and the University of South Florida researchers have advanced a novel compound that specifically targets the endoplasmic reticulum (ER) stress response that is frequently hyperactivated in cancer and promotes survival of cancer cells during stressful conditions.

Newswise: Wistar Earns ‘Exceptional’ Rating for NCI Cancer Center Support Grant for the Second Review Cycle in a Row, Demonstrating Strength of Science
Released: 23-Apr-2019 10:00 AM EDT
Wistar Earns ‘Exceptional’ Rating for NCI Cancer Center Support Grant for the Second Review Cycle in a Row, Demonstrating Strength of Science
Wistar Institute

The Wistar Institute’s Cancer Center has received an “exceptional” rating on its Cancer Center Support Grant (CCSG) application from the National Cancer Institute (NCI) for the second review cycle in a row and the grant has been recommended for renewal, providing $13.6 million to the Cancer Center scientific enterprise.

Released: 5-Apr-2019 11:05 AM EDT
Synthetic DNA-encoded Antibodies Against Zika Virus Shown to be Effective in Preclinical Studies
Wistar Institute

New approach for delivery of DNA-encoded monoclonal antibodies (DMAbs) has been reported by Wistar scientists. This new technology allows direct production of monoclonal antibody-like molecules in living animals.

5-Mar-2019 10:40 AM EST
New Small Molecule Inhibitors Show Potential for Treatment of Epstein-Barr Virus-Associated Cancers
Wistar Institute

Researchers at The Wistar Institute have created a drug candidate for cancers associated with Epstein-Barr Virus (EBV), the virus that causes infectious mononucleosis.

18-Feb-2019 11:00 AM EST
New Insight Into the Balance Between the Tumor-suppressive and Tumor-promoting Effects of Cellular Senescence
Wistar Institute

Researchers at The Wistar Institute have described a novel role of nicotinamide adenine dinucleotide (NAD+) metabolism in the ability of senescent cells to release tumor-promoting molecules.

Released: 14-Feb-2019 10:00 AM EST
Combination of T Cell Therapy and Targeted Therapy as a Novel Strategy for Therapy-resistant Melanoma with Mutations in the BRAF Gene
Wistar Institute

Collaborative research by The Wistar Institute and Moffitt Cancer Center has demonstrated that BRAF targeted therapies render resistant melanoma more sensitive to the attack of killer T cells.

Released: 11-Feb-2019 11:00 AM EST
Federal Funding Fueled Growth of Wistar Science in 2018
Wistar Institute

The Wistar Institute announces that it was awarded more than $16M in federal research funds in support of its groundbreaking research in cancer, immunology and infectious diseases.

5-Feb-2019 4:10 PM EST
Engineered DNA Vaccine Protects Against Emerging Mayaro Virus Infection
Wistar Institute

A novel, synthetic DNA vaccine developed at The Wistar Institute induces protective immunity against Mayaro virus (MAYV), a mosquito-borne infection endemic to South America, that has the potential to become a global emerging viral threat.

22-Jan-2019 4:30 PM EST
Induction of Potent Anticancer Immunity Through Rapid Tumor Antigen Identification and Conversion to Personalized Synthetic DNA Vaccines
Wistar Institute

Wistar scientists and collaborators demonstrated the utility of an optimized synthetic DNA vaccine platform for rapidly inducing immunity against unique combinations of tumor neoantigens.

Newswise: First-in-Class DNA-encoded Monoclonal Antibody Therapy Rapidly Advances into the Clinic
Released: 8-Jan-2019 2:05 PM EST
First-in-Class DNA-encoded Monoclonal Antibody Therapy Rapidly Advances into the Clinic
Wistar Institute

Wistar, along with partners Penn Medicine and Inovio Pharmaceuticals, Inc. announce the FDA has approved the initiation of a first-in-human clinical trial investigating safety and tolerability of a novel synthetic DNA-encoded monoclonal antibody (DMAb) therapeutic technology for the prevention of Zika virus infection.

Released: 5-Dec-2018 3:30 PM EST
Engineered DNA-encoded PCSK9 Inhibitors May Provide an Effective Alternative for Treating High Cholesterol
Wistar Institute

Researchers at The Wistar Institute have developed novel synthetic DNA-encoded monoclonal antibodies (DMAbs) directed against PCSK9, a protein key to regulating cholesterol levels in the bloodstream.

Newswise: Function of Neutrophils During Tumor Progression Unraveled
15-Oct-2018 8:05 AM EDT
Function of Neutrophils During Tumor Progression Unraveled
Wistar Institute

Wistar researchers have characterized the function of neutrophils, a type of white blood cells, during early stages of tumor progression, showing that they migrate from the bone marrow to distant sites and facilitate tumor cell seeding and establishment of metastasis.

10-Oct-2018 9:10 AM EDT
Synthetic DNA Vaccine Against Ebola Virus Shows Potent and Long-term Efficacy in Preclinical Studies
Wistar Institute

A novel synthetic DNA vaccine developed based on technology pioneered by Wistar scientists offers complete protection from Zaire Ebolavirus (EBOV) infection in promising preclinical research.

Released: 8-Oct-2018 10:05 AM EDT
Mechanism of Resistance to Novel Targeted Therapy for Ovarian Cancer Identified
Wistar Institute

Wistar scientists have unraveled a mechanism of resistance to EZH2 inhibitors in ovarian cancers with mutations in the ARID1A gene.

Released: 4-Oct-2018 10:05 AM EDT
Engineered Synthetic DNA-Encoded Checkpoint Inhibitor Antibodies Advance the Field of Cancer Immunotherapy
Wistar Institute

Wistar scientists and collaborators demonstrate for the first time that through engineering constructs, they can express DNA-encoded monoclonal antibodies (DMAbs) targeting CTLA-4, an important cancer checkpoint molecule that blocks anti-cancer immunity.

Released: 27-Sep-2018 11:15 AM EDT
Targeting Multiple Members of a Family of Tumor Antigens with a Synthetic DNA Vaccine Shows Promise for Cancer Immunotherapy
Wistar Institute

Wistar scientists have implemented a novel structurally designed synthetic DNA vaccine to simultaneously target multiple members of a family of proteins that are specifically overexpressed in several types of cancer.

Released: 26-Sep-2018 10:05 AM EDT
Virion Therapeutics, LLC Raises $5 Million to Develop Checkpoint Inhibitor Powered Vaccine Therapies for Treatment of Virally Induced Infectious Diseases & Cancers
Wistar Institute

A new Philadelphia-based start-up, Virion Therapeutics, LLC spun out of The Wistar Institute, will work to advance innovative, immune-based therapies for the treatment of chronic viral-associated cancers and viral infections utilizing the first genetically encoded checkpoint inhibitor that can be given via vaccination.

Released: 6-Sep-2018 1:15 PM EDT
Synthetic DNA Vaccine Effective Against Influenza A Virus Subtype That Is Responsible for More Severe Influenza Seasons
Wistar Institute

Wistar scientists have engineered a synthetic DNA vaccine shown to produce broad immune responses against these H3N2 viruses.

Released: 5-Sep-2018 11:40 AM EDT
Enhancing the Efficacy of Immune Checkpoint Inhibitor Therapy Using a Novel Treatment Combination
Wistar Institute

A combination of a novel inhibitor of the protein CK2 (Casein kinase 2) and an immune checkpoint inhibitor has dramatically greater antitumor activity than either inhibitor alone, according to research from The Wistar Institute that was published online in Cancer Research.

Released: 4-Sep-2018 1:05 PM EDT
Synthetic DNA Technology Provides a Novel Strategy for Effective Delivery of a Complex Anti-HIV Agent
Wistar Institute

Wistar scientists have applied their synthetic DNA technology to engineer a novel eCD4-Ig anti-HIV agent and to enhance its potency in vivo, providing a new simple strategy for constructing complex therapeutics for infectious agents as well as for diverse implications in therapeutic delivery.

Released: 7-Aug-2018 2:45 PM EDT
Wistar Receives Support of More Than $5.5M from Private Foundations and Funding Agencies
Wistar Institute

Wistar received more than $5.5 million in grants and awards from local foundations, and national and international funding agencies to support research, education and training at the Institute.

12-Jun-2018 3:30 PM EDT
Older Melanoma Patients Have Better Response to Immune Checkpoint Blockade Therapy
Wistar Institute

Patient age correlates with response to immunotherapy in melanoma and depleting regulatory T cells in young patients may have a therapeutic potential to enhance response in younger patients, according to research from The Wistar Institute.

Released: 4-Jun-2018 12:05 PM EDT
The Wistar Institute and Harbour BioMed Join Forces to Advance Novel Antibody Therapies for Cancer and Infectious Diseases
Wistar Institute

Wistar and Harbour BioMed announce they have entered into a multi-year, multifaceted research collaboration to co-discover novel antibodies for the treatment of cancer and infectious diseases.

Released: 27-Apr-2018 12:05 PM EDT
Wistar and Ben Franklin Technology Partners of Southeastern Pa. Forge Collaboration to Accelerate Technology Commercialization
Wistar Institute

Wistar and Ben Franklin Technology Partners of Southeastern Pennsylvania (Ben Franklin), a nonprofit conglomerate of partners providing direct/seed funding, mentorship and networks to strengthen enterprise development, have signed a Memorandum of Understanding (MoU) to accelerate the advancement of early-stage life sciences start-ups coming out of Wistar.

25-Apr-2018 12:05 PM EDT
Targeting Telomerase as a Therapeutic Strategy for Difficult-to-Treat Melanoma
Wistar Institute

Targeting telomerase was effective at killing NRAS-mutant melanoma cells, and the impact was further enhanced when the strategy was paired with an inhibitor of mitochondrial function, according to study results by The Wistar Institute published in Oncogene.

Released: 19-Apr-2018 10:05 AM EDT
Wistar Team Receives Prestigious Award from National Clinical Research Forum for DNA-based Zika Research
Wistar Institute

Wistar and partners at the Perelman School of Medicine, University of Pennsylvania; Inovio Pharmaceuticals; and GeneOne Life Science were recognized among the Top 10 Clinical Research Achievement Awards by the Clinical Research Forum for their groundbreaking phase 1 DNA-based Zika vaccine research – the first trial of a Zika vaccine in humans, which proved safe and effective.

18-Apr-2018 10:20 AM EDT
Top HIV Cure Research Team Refutes Major Recent Results on How to Identify HIV Persistence
Wistar Institute

An international team focused on HIV cure research spearheaded by The Wistar Institute in collaboration with the University of Pennsylvania and Vall d’Hebron Research Institute (VHIR) in Barcelona, Spain, established that the CD32 molecule is not a preferential biomarker to identify HIV silent reservoirs within the immune system of patients undergoing antiretroviral therapy (ART), as proposed by a recent landmark study.

Newswise: Soluble Antibodies Play Immune Suppressive Role in Tumor Progression
Released: 12-Apr-2018 2:05 PM EDT
Soluble Antibodies Play Immune Suppressive Role in Tumor Progression
Wistar Institute

Wistar researchers have found that soluble antibodies promote tumor progression by inducing accumulation of myeloid-derived suppressor cells (MDSCs) in pre-clinical cancer models.

11-Apr-2018 2:05 PM EDT
Novel Combination Therapy Effective for NRAS Mutant and Therapy Resistant Melanoma
Wistar Institute

Wistar researchers have identified a novel therapeutic vulnerability in NRAS mutant melanoma and an effective strategy to address it, using a combination of two clinically relevant inhibitors, according to study results published online in EMBO Molecular Medicine.

Released: 27-Mar-2018 12:00 PM EDT
Repurposing Existing FDA-Approved Inhibitors May Provide New Treatment Approach for Ovarian Cancer
Wistar Institute

Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors as a new therapeutic option for ovarian cancer with mutations in the ARID1A gene.

Newswise: Wistar and YourEncore Unite to Advance Life Sciences Opportunities
Released: 23-Mar-2018 1:05 PM EDT
Wistar and YourEncore Unite to Advance Life Sciences Opportunities
Wistar Institute

Wistar and YourEncore, Inc., a life sciences and consumer goods consulting company engaging highly experienced, top talent industry experts, have signed a Memorandum of Understanding (MoU) to help accelerate the advancement of Wistar's early-stage discoveries, start-ups and international collaborations.

21-Mar-2018 10:10 AM EDT
Targeting Telomeres to Overcome Therapy Resistance in Advanced Melanoma
Wistar Institute

A study conducted at The Wistar Institute in collaboration with The University of Texas Southwestern Medical Center has demonstrated the efficacy of targeting aberrantly active telomerase to treat therapy-resistant melanoma.


Showing results

150 of 288

close
0.45381